267 related articles for article (PubMed ID: 35278242)
1. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
[TBL] [Abstract][Full Text] [Related]
2. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
[TBL] [Abstract][Full Text] [Related]
3. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability.
Xu C; Ji G; Chen X; Yan L; Liang T; Liu J; Wang F
Connect Tissue Res; 2023 Mar; 64(2):148-160. PubMed ID: 36379907
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
[TBL] [Abstract][Full Text] [Related]
6. Sostdc1 Suppression in the Absence of Sclerostin Potentiates Anabolic Action of Cortical Bone in Mice.
Choi RB; Hoggatt AM; Horan DJ; Rogers EZ; Loots GG; Robling AG
J Bone Miner Res; 2023 May; 38(5):765-774. PubMed ID: 36891756
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone: An Experimental Study in Nonhuman Primates.
Florio M; Kostenuik PJ; Stolina M; Asuncion FJ; Grisanti M; Ke HZ; Ominsky MS
J Bone Joint Surg Am; 2023 Aug; 105(15):1145-1155. PubMed ID: 37159527
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
[TBL] [Abstract][Full Text] [Related]
9. Mechanically Driven Counter-Regulation of Cortical Bone Formation in Response to Sclerostin-Neutralizing Antibodies.
Gerbaix M; Ammann P; Ferrari S
J Bone Miner Res; 2021 Feb; 36(2):385-399. PubMed ID: 33049076
[TBL] [Abstract][Full Text] [Related]
10. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
[TBL] [Abstract][Full Text] [Related]
11. Genotypic Analyses of the Sclerostin rs851056 and Dickkopf rs1569198 Polymorphisms in Mexican-Mestizo Postmenopausal Osteoporosis: A Case-Control Study.
Vazquez-Villegas ML; Rodriguez-Jimenez NA; Contreras-Haro B; Vasquez-Jimenez JC; Perez-Guerrero EE; Moran-Moguel MC; Sánchez-Rodríguez EN; Villagómez-Vega A; Nuño-Arana I; Becerra-Alvarado IN; Rubio-Arellano ED; Nava-Valdivia CA; Ponce-Guarneros JM; Fajardo-Robledo NS; Nava-Zavala AH; Gonzalez-Lopez L; Saldaña-Cruz AM
Genet Test Mol Biomarkers; 2021 Mar; 25(3):211-217. PubMed ID: 33734895
[No Abstract] [Full Text] [Related]
12. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists.
Holdsworth G; Greenslade K; Jose J; Stencel Z; Kirby H; Moore A; Ke HZ; Robinson MK
Bone; 2018 Feb; 107():93-103. PubMed ID: 29129759
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin Protects Against Vascular Calcification Development in Mice.
De Maré A; Opdebeeck B; Neven E; D'Haese PC; Verhulst A
J Bone Miner Res; 2022 Apr; 37(4):687-699. PubMed ID: 35038187
[TBL] [Abstract][Full Text] [Related]
14. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
15. Decreased Plasma Levels of Sclerostin But Not Dickkopf-1 are Associated with an Increased Prevalence of Osteoporotic Fracture and Lower Bone Mineral Density in Postmenopausal Korean Women.
Lim Y; Kim CH; Lee SY; Kim H; Ahn SH; Lee SH; Koh JM; Rhee Y; Baek KH; Min YK; Kim DY; Kim BJ; Kang MI
Calcif Tissue Int; 2016 Oct; 99(4):350-9. PubMed ID: 27289555
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
[TBL] [Abstract][Full Text] [Related]
17. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
18. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
Ke HZ; Richards WG; Li X; Ominsky MS
Endocr Rev; 2012 Oct; 33(5):747-83. PubMed ID: 22723594
[TBL] [Abstract][Full Text] [Related]
20. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways.
Bouaziz W; Funck-Brentano T; Lin H; Marty C; Ea HK; Hay E; Cohen-Solal M
Arthritis Res Ther; 2015 Feb; 17(1):24. PubMed ID: 25656376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
